Loading
Replace high-dose melphalan and stem-cell rescue with a single infusion of the patient's engineered T cells after induction.
Instead of high-dose melphalan and stem cell rescue, this idea would consolidate newly diagnosed multiple myeloma with a single infusion of ciltacabtagene autoleucel after quadruplet induction. The rationale is that transplant adds progression-free but not overall survival over triplets in DETERMINATION, that cilta-cel improved survival in the second line in CARTITUDE-4, and that earlier use finds fitter T cells and lower tumour burden. The hypothesis is that cilta-cel consolidation gives superior sustained MRD negativity and progression-free survival versus transplant without excess second cancers. CARTITUDE-6 (EMagine) randomises Dara-VRd then cilta-cel against Dara-VRd then transplant, and CARTITUDE-5 tests cilta-cel where transplant is not planned; it is being tested at scale.
One of the most cited trial reports Europe PMC returns for Ciltacabtagene autoleucel in Multiple myeloma, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
One of the most cited trial reports Europe PMC returns for Ciltacabtagene autoleucel in Multiple myeloma, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
One of the most cited reviews Europe PMC returns for Ciltacabtagene autoleucel in Multiple myeloma, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
Shares FDA Approval Summary: Ciltacabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma, Ciltacabtagene autoleucel, CAR-T cell therapy, Multiple myeloma.
Shares CARTITUDE-5, CARTITUDE-4, Ciltacabtagene autoleucel, CAR-T cell therapy.
Shares CARTITUDE-4, Ciltacabtagene autoleucel, CAR-T cell therapy, Multiple myeloma.
Shares Ciltacabtagene autoleucel, CAR-T cell therapy, Multiple myeloma.
Shares Ciltacabtagene autoleucel, CAR-T cell therapy, Multiple myeloma.
Shares CARTITUDE-4, Ciltacabtagene autoleucel, Multiple myeloma.
Shares Ciltacabtagene autoleucel, Newly diagnosed multiple myeloma, transplant-eligible, Multiple myeloma.
Shares CARTITUDE-4, Multiple myeloma.